Kura Oncology
3033 Science Park Road
Suite 220
San Diego
California
92121
United States
Tel: 858-500-8880
Website: http://www.kuraoncology.com/
Email: info@kuraoncology.com
140 articles with Kura Oncology
-
Kura Oncology To Participate In The 2016 Aegis Growth Conference
9/14/2016
-
Kura Oncology To Participate In The 5th Annual Gateway Conference
9/2/2016
-
Kura Oncology To Report Second Quarter 2016 Financial Results
8/3/2016
-
Kura Oncology Announces Data Presentation On Lead Product Candidate Tipifarnib At The Upcoming American Society of Hematology Meeting
12/3/2015
-
Kura Oncology To Present At Upcoming Investor Conference
12/1/2015
-
Kura Oncology To Present At The Oppenheimer 2015 Healthcare Conference
12/1/2015
-
Kura Oncology Announces First Patient Dosed In An Investigator-Sponsored Phase II Trial Of Tipifarnib In Patients With HRAS Mutant Urothelial Cancer
11/30/2015
-
Kura Oncology To Present At The Jefferies 2015 Global Healthcare Conference
11/11/2015
-
Nextech Invest Portfolio Company Kura Oncology Completes Public Offering At NASDAQ
11/9/2015
-
Kura Oncology Announces Pricing Of Public Offering Of Common Stock
11/5/2015
-
Kura Oncology Announces Launch Of Public Offering Of Common Stock
10/29/2015
-
Kura Oncology Appoints Thomas Malley To Board Of Directors
10/14/2015
-
Kura Oncology Initiates Phase II Study Of Tipifarnib In Peripheral T-Cell Lymphoma
9/30/2015
-
Kura Oncology Cleared For Quotation On The OTCQB
9/16/2015
-
Kura Oncology To Present At The 2015 Wedbush Pacgrow Healthcare Conference
8/5/2015
-
Kura Oncology To Present At The Jefferies and Co. 2015 Global Healthcare Conference
5/27/2015
-
Kura Oncology Release: First Patient Dosed In Phase II Study Of Tipifarnib In Advanced Cancers With HRAS Mutations
5/18/2015
-
Faheem Hasnain Joins Kura Oncology Board Of Directors
4/27/2015
-
Kura Oncology's Menin-MLL Inhibitor Program Shows Promise In Study Published In Cancer Cell; Program Targeting Acute Leukemias Licensed From University of Michigan
3/30/2015
-
Led By a Serial Biotech Entrepreneur, Kura Oncology Forges Pact With Johnson & Johnson Unit and Bags $60 Million to Work on Shelved Drug
3/13/2015